期刊
JOURNAL OF NEUROLOGY
卷 261, 期 4, 页码 651-654出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-013-7032-x
关键词
Glioblastoma; Oligodendroglioma; Bevacizumab; Temozolomide; PCV
The management of high-grade glioma (HGG) has evolved significantly over the last decade. Patients are managed in a multidisciplinary team setting in order to ensure their care is guided by the most current evidenced based treatments. The outcome in patients with HGG, while still poor, has improved in terms of both survival and quality of life during illness. This review discusses a number of developments seen in the management of HGG over the last 5 years.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据